
    
      80 patients will be included in swiss-romande hospitals and private oncologists and followed
      by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration
      is 48 weeks, with a motivational interviewing at least every three months. Patient adherence
      will be assessed electronically by MEMS (Medication Event Monitoring System).
    
  